Local control in non-metastatic medulloblastoma

References

• Smee RI, Williams JR, De-Loyde KJ, Meagher NS, Cohn R. Medulloblastoma: Progress over time. J Med Imaging Radiat Oncol 2012;56:227–34.
   PubMed Web of Science ®Google Scholar
• Fossati P, Ricardi U, Orecchia R. Pediatric medulloblastoma: Toxicity of current treatment and potential role of protontherapy. Cancer Treat Rev 2009;35:79–96.
   PubMed Web of Science ®Google Scholar
• Frange P, Alapetite C, Gaboriaud G, Bours D, Zucker JM, Zerah M, et al. From childhood to adulthood: Long-term outcome of medulloblastoma patients. The Institut Curie experience (1980–2000). J Neurooncol 2009;95:271–9.
   Google Scholar
• Packer RJ, Zhou T, Holmes E, Vezina G, Gajjar A. Survival and secondary tumors in children with medulloblastoma receiving radiotherapy and adjuvant chemotherapy: Results of Children’s Oncology Group trial A9961. Neuro Oncol 2013;15:97–103.
   PubMed Web of Science ®Google Scholar
• Lackner H, Benesch M, Schagerl S, Kerbl R, Schwinger W, Urban C. Prospective evaluation of late effects after childhood cancer therapy with a follow-up over 9 years. Eur J Pediatr 2000;159:750–8.
   PubMed Web of Science ®Google Scholar
• Christopherson KM, Rotondo RL, Bradley JA, Pincus DW, Wynn TT, Fort JA, et al. Late toxicity following craniospinal radiation for early-stage medulloblastoma. Acta Oncol 2014;53:471–80.
   PubMed Web of Science ®Google Scholar
• Massimino M, Casanova M, Polastri D, Biassoni V, Modena P, Pecori E, et al. Relapse in medulloblastoma: What can be done after abandoning high-dose chemotherapy? A mono-institutional experience. Childs Nerv Syst Epub2013 Apr 18.
   Google Scholar
• Warmuth-Metz M, Blashofer S, von Bueren AO, von Hoff K, Bison B, Pohl F, et al. Recurrence in childhood medulloblastoma. J Neurooncol 2011;103:705–11.
   PubMed Web of Science ®Google Scholar
• Rieken S, Mohr A, Habermehl D, Welzel T, Lindel K, Witt O, et al. Outcome and prognostic factors of radiation therapy for medulloblastoma. Int J Radiat Oncol Biol Phys 2011;81:e7–13.
   Google Scholar
• Zeltzer PM, Boyett JM, Finlay JL, Albright AL, Rorke LB, Milstein JM, et al. Metastasis stage, adjuvant treatment, and residual tumor are prognostic factors for medulloblastoma in children: Conclusions from the Children’s Cancer Group 921 randomized phase III study. J Clin Oncol 1999;17: 832–45.
   PubMed Web of Science ®Google Scholar
• Tait DM, Thornton-Jones H, Bloom HJ, Lemerle J, Morris-Jones P. Adjuvant chemotherapy for medulloblastoma: The first multi-centre control trial of the International Society of Paediatric Oncology (SIOP I). Eur J Cancer 1990;26:464–9.
   PubMed Web of Science ®Google Scholar
• Evans AE, Jenkin RD, Sposto R, Ortega JA, Wilson CB, Wara W, et al. The treatment of medulloblastoma. Results of a prospective randomized trial of radiation therapy with and without CCNU, vincristine, and prednisone. J Neurosurg 1990;72:572–82.
   Google Scholar
• Stavrou T, Bromley CM, Nicholson HS, Byrne J, Packer RJ, Goldstein AM, et al. Prognostic factors and secondary malignancies in childhood medulloblastoma. J Pediatr Hematol Oncol 2001;23:431–6.
   PubMed Web of Science ®Google Scholar
• McNeil DE, Cote TR, Clegg L, Rorke LB. Incidence and trends in pediatric malignancies medulloblastoma/primitive neuroectodermal tumor: A SEER update. Surveillance Epidemiology and End Results. Med Pediatr Oncol 2002; 39:190–4.
   PubMedGoogle Scholar
• Taylor RE, Bailey CC, Robinson K, Weston CL, Ellison D, Ironside J, et al. Results of a randomized study of preradiation chemotherapy versus radiotherapy alone for nonmetastatic medulloblastoma: The International Society of Paediatric Oncology/United Kingdom Children’s Cancer Study Group PNET-3 Study. J Clin Oncol 2003;21:1581–91.
   PubMed Web of Science ®Google Scholar
• von Bueren AO, von Hoff K, Pietsch T, Gerber NU, Warmuth-Metz M, Deinlein F, et al. Treatment of young children with localized medulloblastoma by chemotherapy alone: Results of the prospective, multicenter trial HIT 2000 confirming the prognostic impact of histology. Neuro Oncol 2011;13:669–79.
   PubMed Web of Science ®Google Scholar
• Jones DT, Jager N, Kool M, Zichner T, Hutter B, Sultan M, et al. Dissecting the genomic complexity underlying medulloblastoma. Nature 2012;488:100–5.
   PubMed Web of Science ®Google Scholar
• Northcott PA, Jones DT, Kool M, Robinson GW, Gilbertson RJ, Cho YJ, et al. Medulloblastomics: The end of the beginning. Nat Rev Cancer 2012;12:818–34.
   PubMed Web of Science ®Google Scholar
• Brasme JF, Grill J, Doz F, Lacour B, Valteau-Couanet D, Gaillard S, et al. Long time to diagnosis of medulloblastoma in children is not associated with decreased survival or with worse neurological outcome. PLoS One 2012;7:e33415.
   PubMed Web of Science ®Google Scholar
• Paulino AC, Mazloom A, Teh BS, South M, Okcu MF, Su J, et al. Local control after craniospinal irradiation, intensity-modulated radiotherapy boost, and chemotherapy in childhood medulloblastoma. Cancer 2011;117:635–41.
   PubMed Web of Science ®Google Scholar
• Merchant TE, Kun LE, Krasin MJ, Wallace D, Chintagumpala MM, Woo SY, et al. Multi-institution prospective trial of reduced-dose craniospinal irradiation (23.4 Gy) followed by conformal posterior fossa (36 Gy) and primary site irradiation (55.8 Gy) and dose-intensive chemotherapy for average-risk medulloblastoma. Int J Radiat Oncol Biol Phys 2008;70:782–7.
   PubMed Web of Science ®Google Scholar
• Kawaguchi N, Sundberg C, Kveiborg M, Moghadaszadeh B, Asmar M, Dietrich N, et al. ADAM12 induces actin cytoskeleton and extracellular matrix reorganization during early adipocyte differentiation by regulating beta1 integrin function. J Cell Sci 2003;116:3893–904.
   PubMed Web of Science ®Google Scholar
• Carrie C, Grill J, Figarella-Branger D, Bernier V, Padovani L, Habrand JL, et al. Online quality control, hyperfractionated radiotherapy alone and reduced boost volume for standard risk medulloblastoma: Long-term results of MSFOP 98. J Clin Oncol 2009;27:1879–83.
   PubMed Web of Science ®Google Scholar
• Packer RJ, Vezina G. Management of and prognosis with medulloblastoma: Therapy at a crossroads. Arch Neurol 2008;65:1419–24.
   PubMedGoogle Scholar
• Taylor MD, Northcott PA, Korshunov A, Remke M, Cho YJ, Clifford SC, et al. Molecular subgroups of medulloblastoma: The current consensus. Acta Neuropathol 2012;123: 465–72.
   PubMed Web of Science ®Google Scholar